The renin-angiotensin system and its role in cardiovascular pathophysiology and therapeutis;Sistema renina-angiotensina e seu papel na fisiopatologia e terapêutica cardiovascular

Revista Portuguesa de Cardiologia

Volumn 23, Issue SUPPL. 2, 2004, Pages

  Castro Chaves, Paulo ^a   Leite Moreira, Adelino F ^a,b  

^a University of Porto   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Angiotensin; Arterial hypertension; Cardiovascular; Heart failure; Renin

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; PLATELET DERIVED GROWTH FACTOR;

ADRENAL FUNCTION; ADRENERGIC SYSTEM; ALDOSTERONE RELEASE; APOPTOSIS; BLOOD PRESSURE REGULATION; BRAIN FUNCTION; CARDIOVASCULAR DISEASE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HEART FUNCTION; HEART INFARCTION; HOMEOSTASIS; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY FUNCTION; NERVE STIMULATION; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOOTH MUSCLE FIBER; SODIUM ABSORPTION;

ANGIOTENSIN II; CARDIOVASCULAR DISEASES; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 3142702121     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Tigerstedt R, Bergman PG. Niere und Kreislauf. Skand Arch Physiol. 1898;8:223-71.
2. Braun-Menéndez E, Fasciolo JC, Leloir LF, Muñoz JM. La sustancia hipertensora de la sangre del riñón isquemiado. Rev Soc Arg Biol 1939;15:420-5.
3. Braun-Menéndez E, Fasciolo JC, Leloir LF, Muñoz JM, Taquini AC. Hipertensión Arterial Nefrógena. Buenos Aires, Argentina: El Ateneo 1943.
4. Page IH, Helmer OM. A crystalline pressor substance: angiotonin. Proc Center Soc Clin Invest 1939;12:17.
5. Braun-Menéndez E, Page IH. Suggested revision of nomenclature: an-giotensin. Science 1958;127:242.
6. Basso N, Terragno NA. History about the discovery of the Renin-Angiotensin System. Hypertension 2001;38:1246-9.
7. Dzau VJ, Gibbons GH. Autocrine and paracrine mechanisms of vascular myocytes in systemic hypertension. Am J Cardiol 1987;60:991-1031.
8. Weber KT, Sun Y, Campbell SE. Structural remodelling of the heart by fibrous tissue: Role of circulating hormones and locally produced peptides. Eur Heart J 1995;16 (Suppl N):12-8.
9. Touys RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth cells. Pharmacol Rev 2000;52:639-72.
10. De Gasparo M, Catt KJ, Wright JW, Unger TH. International Union of Pharmacology. XXIII. The Angiotensin II Receptors. Pharmacol Rev 2000;52:415-72.
11. Ruiz-Ortega M, Lorenzo O, Rupérez M, Esteban V, Susuki Y, Mezzano S, Plaza JJ, Egido J. Role of the Renin-Angiotensin System in Vascular Diseases - Expanding the field. Hypertension, 2001;38:1382-7.
12. Kim S, Iawo H. Molecular and Cellular Mechanisms of Angiotensin II - Mediated Cardiovascular and Renal Diseases. Pharmacol Rev 2001;52:11-34.
13. Skeggs LT, Lentz KE, Gould AB, Hochstrasser H Kahn Jr. Biochemistry and kinetics of the renin-angiotensin system. Fed Proc 1967;26:42-7.
14. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counter-regulatory actions of angiotensin (1-7). Hypertension 1997:30:535-41.
15. Esther CR, Marino EM, Howard TE. The critical role of tissue angiotensin-converting enzmes as revealed by gene targeting in mice. J Clin Invest 1997;99:2375-85.
16. Dostal DE, Baker KM. The cardiac renin angiotensin system: conceptual or a regulator of cardiac function? Circ Res 1999;85:643-50.
17. Gohlke P, Bunning P, Unger T. Distribution and metabolism of angiotensin I and II in the blood vessel wall. Hypertension 1992;20:151-7.
18. Wiemer G, Scholkens BA, Becker RHA, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradikinin. Hypertension 1991;18:558-63.
19. Linz W, Wohlfart P, Scholkens BA, Malinski T, Wiemer G. Interactions among ACE, Kinins and NO. Cardiov Res 1999;43:549-61.
20. Welches WR, Brosnihan KB, Ferrario CM. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase. Life Sci 1993;52:1461-80.
21. Ferrario CM. Angiotensin 1-7 and antihypertensive mechanisms. J Nephrol 1998;11:278-83.
22. Tallant EA, Lu X, Weiss RB, Cappell MC, Ferrario CM. Bovine aortic endothelial cells contain an angiotensin 1-7 receptor. Hypertension 1997;29 (part 2):388-9.
23. Seyedi N, Xu X, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 1995;26:164-70.
24. Li P, Chappell MC, Ferrario CM, Brosnihan KB. Angiotensin 1-7 augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension 1997 (part 2) 9:394-400.
25. Moriguchi A, Brosnihan KB, Kumagai H, Ganten D, Ferrario CM. Mechanism of hypertension in transgenic rats expressing the mouse ren-2-gene. Am J Physiol 1994;266: R1273-R1279.
26. Loot AE, Roks AJ, Henning RH, Tio RA, Suurmeijer AJ, Boomsma F, van Gilst WH. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation. 2002;105:1548-50.
27. Strawn WB, Ferrario CM, Tallant EA. Angiotensin 1-7 reduces smooth muscle growth after vascular injury. Hypertension 1999;33 (part 1):207-11.
28. Ferrario CM. Does Angiotensin 1-7 contribute to cardiac adaptation and preservation of endothelial function in heart failure? Circulation 2002;105:1523-5.
29. Allen AM, Zhuo J, Mendelsohn FA. Localization of angiotensin AT1 and AT2 receptors. J Am Soc Nephrol. 1999;10 Suppl 11:S23-9.
30. Tsutsumi K, Saavedra JM. Characterization of AT-2 angiotensin recetors in rat anterior cerebral arteries. Am J Physiol 1991;261:H667-H670.
31. Jackson EK, Herzer WA. Regional vascular selectivity of Ang II. J Pharmacol Exp Ther 2001;297:736-45.
32. Lopez JJ, Lorell BH, Ingelfinger JR, Weinberg EO, Schunkert H, Diamant D, Tang SS. Distribution and function of cardiac angiotensin AT-1 and AT-2 receptor subtypes in hypertrophied rat hearts. Am J Physiol 1994;267:H844-H852.
33. Wharton J, Morgan K, Rutherford RAD, Catravas JD, Chester A, Whitehead BF, de Leval MR, Yacoub MH, Polack JM. Differential distribution of angiotensin AT-2 receptors in the normal and failing human heart. J Pharmacol Exp Ther 1998;284:323-36.
34. Wagner J, Gehlen F, Ciechanowicz A, Ritz E.Angiotensin II receptor type1 gene expression in human glomerulonephritis and diabetes mellitus. J Am Soc Nephrol 1999;10:545-51.
35. Oliverio MI, Kim H-S, Ito M, Le T, Audoly L, Best CF, Hiller S, Kluckman K, Maeda N, Smithies O, Coffman TM. Reduced growth, abnormal kidney struc-ture, and type 2 (AT 2) angiotensin receptor-mediated blood pressure regulation in mice lacking both AT 1A and AT 1B receptors for angiotensin II. Proc Natl Acad Sci USA 1998;95:15496-501.
36. De Gasparo M, Whitebread S, Kalenga MK, de Hertogh R, Crevoisier P, Thomas K. Down regulation of the angiotensin II receptor subtype AT 2 in human myometrium during pregancy. Regul Pept 1994;53:39-45.
37. Busche S, Gallinat S, Bohle RM, Reinecke A, Seebeck J, Franke F, Fink L, Zhu M, Sumners C, Unger T. Expression of angiotensin AT(1) and AT(2) receptors in adult rat cardiomyocytes after myocardial infarction. A single-cell reverse transcriptase-polymerase chain reaction study. Am J Pathol 2000;157:605-11.
38. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioral and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995;377:744-7.
39. Masaki H, Kurihara T, Yamaki A, Inomata N, Nozawa Y, Mori Y, Murasawa S, Kizima K, Maruyama K, Horiuchi M, Dzau V, Takahashi H, Iwasaka T, Inada M, Matsubara H. Cardiac-specific overexpression of angiotensin II AT-2 receptor causes attenuated response to AT-1 receptor-mediated pressor and chronotropic effects. J Clin Invest 1998;101:527-35.
40. Chaki S, Inagami T. Identification and characterization of a new binding site for angiotensin II in mouse neoroblastoma neuro-2A cells. Biochem Biophys Res Commun 1992;182:388-94.
41. Roberts KA, Krebs LT, Kramár EA, Shaffer MJ, Harding JW, Wright JW. Autoradiographic identification of brain angiotensin IV binding sites and differential c-Fos expression following intracerebroventricular injection of angiotensin II and IV in rats. Brain Res 1995;682:13-21.
42. Hein L, Meinel L, Pratt RL, Dzau VJ, Kobilka BE. Intracellular trafficking of angiotensin II an dits AT-1 and AT-2 receptors: evidence for selective sorting of receptor and ligand. Mol Endocrinol 1997;11:1266-77.
43. De Mello WC, Danser AHJ. Angiotensin and the heart. On the intracrine renin-angiotensin systema. Hypertension 2000;1183-1118.
44. Berry C, Touys R, Dominiczak AF, Webb RC, Jonhs DG. Angiotensin receptors: signaling, vascular pathophysiology and interactions with ceramide. Am J Physiol Heart Circ Physiol 2001;281:H2337-H2365.
45. Zhang C, Hein TW, Wang W, Kuo L. Divergent roles of angiotensin II AT-1 and AT-2 receptors in modulating coronary microvascular function. Circ Res 2003;92:322-9.
46. Weber KT. Aldosterone in congestive heart failure. NEJM 2001;345:1689-97.
47. Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit-Faisant B, Carayon A, Swynghedauw B, Delcayre C. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation. 1999;99:2694-701.
48. Van Leeuwen RTJ, Kol A, Andreotti F, Kluft C, Maseri A, Sperti G. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994;90:362-8.
49. Rakugi H, Wang D, Dzau VJ, Pratt RE. Potential importance of tissue angiotensin converting enzyme inhibition in preventing neointima formation. Circulation 1994;90:449-55.
50. Horiuchi M, Akishiita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999;33:613-21.
51. Abdalla S, Lother H, Abdel-Tawab AM, Quitterer U. The Angiotensin II AT-2 receptor is an AT-1 receptor antagonist. J Biol Chem 2001;276:39721-6.
52. Ford WR, Clanachan AS, Jugdutt BI. Opposite effects of angiotensin AT-1 and AT-2 receptor antagonists on recovery of mechanical function after ischemia-reperfusion in isolated working rat hearts. Circulation 1996;94:3087-9.
53. Levy BI, Benessiano J, Henrion D, Caputo L, Heymes C, Duriez M, Poitevin P, Samuel JL. Chronic blockade of AT-2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest 1996;98:418-25.
54. Ruiz-Ortega M, Lorenzo O, Ruperez M, Konig S, Wittig B, Egido J. Angiotensin II activates nuclear transcription factor-kB through AT-1 and AT-2 in vascular smooth muscle cells: molecular mechanisms. Circ Res 2000;86:1266-72.
55. Xu Y, Clanachan A, Jugdutt B. Enhanced expression of angiotensin II type 2 receptor, IP3 and protein kinase ce during cardioprotection induced by angiotensin II type 2 receptor blockade. Hypertension 2000;35:506-10.
56. Opie L, Sack MN. Enhanced angiotensin II activity in heart failure: reevaluation of the counterregulatory hypothesis of receptor subtypes. Cir Res 2001;88:654-8.
57. Noda K, Feng YH, Liu XP, Saad Y, Husain A, Karnik SS. The active state of the AT 1 angiotensin receptor is generated by angiotensin II induction. Biochemistry 1996;35:16435-42.
58. Rhee SG, Choi KD. Regulation of inositol phospholipid-specific phospho-lipase C isozymes. J Biol Chem 1992;267:12393-6.
59. Ushio-Fukai M, Alexander RW, Akers M, Griendling KK. p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. J Biol Chem 1998;271:15022-9.
60. Griendling KK, Tsuda T, Berk BC, Alexander RW. Angiotensin II stimulation of vascular smooth muscle. J Cardiovasc Pharmacol 1989;14 (Suppl 6):S27-S33.
61. Touyz RM, Schiffrin EL. Role of calcium influx and intracellular calcium stores in angiotensin II-mediated calcium hyperresponsiveness in smooth muscle from spontaneously hypertensive rats. J Hypertens 1997;15:1431-9.
62. Touyz RM, He G, Deng L Y, Schiffrin EL. Role of extracellular signal-regulated kinases in angiotensin II-stimulated contraction of smooth muscle cells from human resistance vessels. Circulation 1999;99:392-9.
63. Damron DS, Nadim HS, Hong SJ, Darvish A, Murray PA. Intracellular translocation of PKC isoforms in canine pulmonary artery smooth muscle cells by Ang II. Am J Physiol 1998;274:L278-L288.
64. Touyz RM, El Mabrouk M, Schiffrin EL. MEK inhibition attenuates Ang II-mediated signaling and contraction in SHR vascular smooth muscle cells. Circ Res 1999;84:505-15.
65. Li JS, Touyz RM, Schiffrin EL. Effects of AT 1 and AT 2 receptor antagonists on blood pressure and small artery structure in angiotensin II-infused rats. Hypertension 1998;31:487-92.
66. Balmforth AJ, Shepherd FH, Warburton P, Ball SG. Evidence of an important and direct role for protein kinase C in agonist-induced phosphorylation leading to desensitization of the angiotensin AT 1A receptor. Br J Pharmacol 1997;122:1469-77.
67. Sayeski PP, Ali MS, Harp JB, Marrero MB, Bernstein KE. Phosphorylation of p130 Cas by angiotensin II is dependent on c-Src, intracellular Ca 21, and protein kinase C. Circ Res 1998;82:1279-88.
68. Hefti MA, Harder BA, Eppenberger HM, Schaub MC. Signaling pathways in cardiac myocyte hypertrophy. J Mol Cell Cardiol 1997;29:2873-92.
69. Howe A, Aplin AE, Alahari SK, Juliano RL. Integrin signaling and cell growth control. Curr Opin Cell Biol 1998;10:220-31.
70. Honda H, Oda H, Nakamoto T, Honda Z, Sakai R, Suzuki T, Saito T, Nakamura K, Nakao K, Ishikawa T, Katsuki M, Yazaki M, Hirai H. Cardiovascular anomaly, impaired actin bundling and resistance to Src-induced transformation in mice lacking p130Cas. Nat Genet 1998;19:361-5.
71. Leevers SJ, Vanhaesebroek B, Waterfield MD. Signaling through phos-phoinositide 3-kinases: The lipids take centre stage. Curr Opin Cell Biol 1999;11:219-25.
72. Sudgen PH, Clerk A. Stress responsive mitogen activated protein kinases in the myocardium. Circ Res 1998;24;345-52.
73. Bueno OF, Molkentin JD. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res 2002;91:776-81.
74. New L, Han J. The p38 MAP Kinase pathway and its biological function. Trends Cardiovasc Med 1998;8:220-9.
75. Dulin NO, Alexander LD, Harrwalkar S, Falck Jr, Douglas JG. Phospho-lipase A2-mediated activation of mitogen-activated protein kinase by angiotensin II. Proc Natl Acad Sci USA 1998;95:8098-102.
76. Lassègue B, Alexander RW, Clark M, Akers MA, Griendling KK. Phosphatidylcholine is a major source of phosphatidic acid and diacylglycerol in angio-tensin II-stimulated vascular smooth muscle cells. Biochem J 1993;292:509-17.
77. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahashi H, Iwasaka T. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest. 1999;104:925-35.
78. Caputo L, Benessiano J, Boulanger CM, Levy BI. Angiotensin II increases cGMP content via endothelial angiotensin II AT 1 subtype receptors in the rat carotid artery. Arterioscler Thromb Vasc Biol 1995;15:1646-51.
79. McIntyre M, Bohr DF, Dominiczak AF. Endothelial functin in hypertension. The role of superoxide anion. Hypertension 1999;34:539-45.
80. Landmesser U, Spiekermann S, Dikalov S, Tatge H, Wilke R, Kohler C, Harrison DG, Hornig B, Drexler H. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation. 2002;10;106:3073-8.
81. Schultz Jel J, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, Kimball TR, Doetschman T. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest. 2002;109:787-96.
82. Moreau P, d'Uscio LV, Shaw S, Takase H, Barton M, Luscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation. 1997;96:1593-7.
83. Chen YQ, Gilliam DM, Rydzewski B, Naftilan AJ. Multiple enhancer elements mediate induction of c-fos in vascular smooth muscle cells. Hypertension 1998;27:1224-33.
84. Nadal-Ginard B, Kajstura J, Leri A, Anversa P. Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ Res 2003;92:139-50.
85. Diep QN, El Mabrouk M, Yue P, Schiffrin EL. Effect of AT(1) receptor blockade on cardiac apoptosis in angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol. 2002;282:H1635-41.
86. Gonzalez A, Lopez B, Querejeta R, Diez J. Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease? J Mol Cell Cardiol. 2002;34:1585-93.
87. Kurisu S, Ozono R, Oshima T, Kambe M, Ishida T, Sugino H, Matsuura H, Chayama K, Teranishi Y, Iba O, Amano K, Matsubara H. Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension. 2003;41:99-107.
88. Taubman MB. Angiotensin II: a vasoactive hormone with ever increasing biological roles. Cir Res 2003;92:9-11.
89. Campos AH, Zhao Y, Pollman MJ, Gibbons GH. DNA microarray profiling to identify angiotensin-responsive genes in vascular smooth muscle cells: potential mediators of vascular disease. Circ Res 2003;10;92:111-8.
90. + exchanger and cardiac hypertrophy. Circ Res 1998;83:870-3.
91. Rossi GP, Sacchetto A, Cesari M, Pessina AC. Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res. 1999;43:300-7.
92. Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, Nogami A, Murumo F, Hiroe M. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest. 1993;92:398-403.
93. Nakano A, Kishi F, Minami K, Wakabayashi H, Nakaya Y, Kido H. Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J Immunol. 1997;159:1987-92.
94. Castro-Chaves P, Roncon-Albuquerque R Jr, Lima-Carneiro A, Lopes T, Leite-Moreira AF. O efeito inotrópico positivo da angiotensina II é modulado pelo endotélio endocárdico e pela endotelina-1. Revista Portuguesa de Cardiologia 2002;21 (supl. I):22.
95. Castro-Chaves P, Roncon-Albuquerque R Jr, Leite-Moreira AF. Modulation of the positive inotropic effect of angiotensin II by the endocardial endothelium and endothelin-1. European Heart Journal 2002;23 (Abstr. Suppl.)
96. Bodin P, Travo C, Stoclet JC, Travo P. High sensitivity of hypertensive aortic myocytes to norepinephrine and angiotensin. Am J Physiol 1993;264:C441-C445.
97. Kim HS, Krege JH, Kluckman KD, Hagaman JR, Hodgin JB, Best CF, Jennette JC, Coffman TM, Maeda N, Smithies O. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA. 1995;92:2735-9.
98. Lee WK, Padmanabhan S, Dominiczak AF. Genetics of hypertension: from experimental models to clinical applications. J Hum Hypertens 2000;14:631-47.
99. Serneri GG, Boddi M, Cecioni I, Vanni S, Coppo M, Papa ML, Bandinelli B, Bertolozzi I, Polidori G, Toscano T, Maccherini M, Modesti PA. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res 2001;88:961-8.
100. Paradis P, Dali-Youcef N, Paradis FW, Thibault G, Nemer M. Overexpression of angiotensin II type 1 receptor in cardiomyocytes induces cardiac hypertrophy and remodelling. Proc Natl Acad Sci USA 2000;97:931-6.
101. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998;83:1182-91.
102. Schneider MD, Lorell BH. AT-2 judgement day. Which angiotensin receptor is the culprit in cardiac hypertrophy? Circulation 2001;104:247-8.
103. Ichihara S, Senbonmatsu T, Price E Jr, Ichiki T, Gaffney FA, Inagami T. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation 2001;104:346-51.
104. Kim S, Wanibuchi H, Hamaguchi A, Miura K, Yamanaka S, Iwao H. Angiotensin blockade improves cardiac and renal complications of type II diabetic rats. Hypertension 1997;30:1054-61.
105. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998;31:181-8.
106. McMurray J, Pfeffer MA. New therapeutic options in congestive heart failure: Part I. Circulation 2002;30;105:2099-106.
107. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandanavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
108. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
109. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-77.
110. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355:1575-81.
111. Pitt B, Poole-Wilson PA, Segal R. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-7.
112. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
113. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.